Weight Loss & Metabolic Health
What Is the GLP-1 and Sleep Apnea?
Last reviewed: May 2026 · Haute MD Editorial Team
GLP-1 medications, particularly tirzepatide, significantly improve obstructive sleep apnea (OSA) in adults with obesity. The SURMOUNT-OSA trials (2024) showed up to 63% reduction in apnea-hypopnea index, with many patients improving enough to discontinue CPAP. Tirzepatide is now FDA-approved for moderate-to-severe OSA in adults with obesity.
The SURMOUNT-OSA findings
Two trials enrolled 469 adults with obesity and moderate-to-severe OSA. Tirzepatide reduced AHI by 25 to 30 events per hour on average — equivalent to or better than CPAP for many patients. Improvements correlated with weight loss but exceeded what weight loss alone would predict.
How it works
Weight loss reduces upper airway fat and improves chest wall mechanics. GLP-1 receptors in the brainstem may also directly influence respiratory control during sleep.
Who should consider it
Adults with obesity (BMI 30+) and confirmed moderate-to-severe OSA. Particularly useful for CPAP-intolerant patients or those seeking long-term resolution rather than mask-based management.
Frequently Asked Questions
Can I stop my CPAP?
Some patients can after significant weight loss and confirmed improvement on repeat sleep study. Do not stop without physician guidance.
Does semaglutide work too?
Likely yes, though tirzepatide has the FDA indication and strongest data.
How long until OSA improves?
Many patients see improvement within 6 to 12 months, paralleling weight loss.
Is OSA a covered indication?
Tirzepatide for OSA may be covered separately from weight loss indication — check with insurer.
Get Help Now
Speak with a Haute MD Internal Medicine physician
Dr. Alexander Golberg
Internal Medicine · New York, NY
View Profile
Dr. Kern Brar
MD
Internal Medicine · Oceanside, CA
View ProfileAre you a Internal Medicine physician?
Join Haute MD Network and have your profile featured alongside these answers.
Apply for the NetworkRelated Guides
Guide · WEIGHT LOSS & METABOLIC HEALTH
What Is Tirzepatide?
Tirzepatide is a dual GIP/GLP-1 receptor agonist (Mounjaro, Zepbound) that produces 20%+ weight loss in clinical trials. Learn how it works.
Read GuideGuide · WEIGHT LOSS & METABOLIC HEALTH
What Is the GLP-1 and Cardiovascular Benefit?
GLP-1 medications like semaglutide (Ozempic, Wegovy) have demonstrated significant cardiovascular benefits beyond weight loss. The SELECT trial showed a.
Read GuideGuide · WEIGHT LOSS & METABOLIC HEALTH
What Is the GLP-1 and Fatty Liver?
GLP-1 medications significantly improve metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD) and its more severe form MASH.
Read Guide